Durvalumab vs Osimertinib

Durvalumab vs Osimertinib: Overview

This comparison examines the pharmacological differences between Durvalumab and Osimertinib.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Osimertinib — 48 hours.

Chemical Properties

Molecular Formula: Osimertinib — C28H33N7O2.

Molecular Weight: Osimertinib — 499.6050 g/mol.

Type: Durvalumab — Antibody; Osimertinib — Small molecule.